Reports Q3 revenue $260K, consensus $285K. The company states, “There is a palpable level of excitement and activation energy coursing through our company as we prepare to submit our application for approval of our first molecular diagnostic test kit for clinical use, GraftAssureDx, to the FDA. We expect to begin selling the product next year after we achieve regulatory marketing authorization.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study
- Insight Molecular says kidney transplant patient achieved ‘immune reset’
- Insight Molecular Diagnostics Extends Executive Employment Agreement
- Insight Molecular Diagnostics announces attendance at two industry conferences
- Insight Molecular Diagnostics Approves Executive Salary Increases